Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glow-in-the-Dark dye helps surgeons spot hidden cancer

NCT ID NCT07039526

Recruiting now Diagnosis Sponsor: John Waters Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a dye called CYTALUX (pafolacianine) that attaches to cancer cells and glows under a special camera during surgery. About 50 adults with certain cancers (like esophageal, pancreatic, or gynecologic) will get the dye before surgery. The goal is to see if the glowing helps surgeons find and remove tumors that are not visible under normal light. Participation lasts about 2 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pafolacianine (CYTALUX)
What this could lead to
If it works, this could help surgeons see and remove more cancer during surgery, potentially improving outcomes.
What could go wrong
This is a small early-phase study (50 people) testing an already-approved drug for a new use. It may not work for all cancer types, and the dye could cause allergic reactions or false positives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm esophageal cancer Esophageal Neoplasms female reproductive organ cancer hepatobiliary neoplasm malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER GASTROINTESTINAL CANCERS GYNECOLOGIC CANCERS

Contacts and locations

Locations

  • Clemments University Hospital

    RECRUITING

    Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.